skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

See how you can maximize your drug’s market potential in a payer-dominated world

RxScorecard | Pharma intelligence

The balance of power behind the prescribing decision is changing: payers are ever more in charge. That means that insight into how payers make decisions - how they evaluate drugs, one against another - will be crucial to any successful drug launch.

How it works

RxScorecard™ objectively shows how your payer customers will see your product and your competitors'. Access scores for competitive drugs on all key efficacy, safety, adherence, and economic metrics most meaningful for payers, and gain powerful insight on how you can effectively differentiate your product and maximize your drugs market potential.

RxScorecard helps you to:

  • Define your development path and specific data requirements that differentiate pipeline candidates to payers
  • Reveal where the disproportionate value of your drug lies alongside competitors, from a payer’s perspective
  • See how the comparative value of a drug is differentiated within a therapeutic area by class and patient sub-population
  • Align internal stakeholders around a common understanding of what payers value
  • Create custom scenarios, using your own proprietary data, to test the impact of different assumptions

What's included

productfeature

​An evidence based payer supported web based tool

View the relative value of marketed and pipeline agents by therapeutic area and patient population, all from a payer’s perspective

clinical and economic metrics company analysis pharma intelligence

Clinical and economic metrics

Access scores for competitive drugs on up to 36 efficacy, safety, adherence and economic metrics most meaningful for payers

company analysis pharma intelligence

Transparent scoring methodology

All data points are supported by embedded links to the most up-to-date evidence available

company developments pharma intelligence

Interactive and customizable framework

Create different data scenarios & add proprietary data to see where you can improve your drug’s value proposition.  Perform real-time war gaming.

Pharma Intelligence: latest

Meet the team

Management

Roger Longman

Management, Leadership Manager
Roger Longman

+26 year(s) experience

Management

Beth Nash

Management, MD Chief Medical Officer
Beth Nash

Beth specializes in

  • Commercial Strategy

+21 year(s) experience

Management

Christine Blazynski PhD

Management, Innovation Head Informa Pharma Intelligence
Christine Blazynski PhD

Christine specializes in

  • Clinical Trials
  • Clinical trial strategy
  • Clinical trial benchmark analysis
  • Clinical trend analysis
  • Biopharma pipeline strategy

+20 year(s) experience

How we've helped other businesses

"We at GSK believe that it’s critical for the pharmaceutical industry to produce drugs that deliver value for patients, providers and payers. We have found RxScorecard™ to be an insightful framework for assessing and comparing the value of drugs, both marketed and developmental assets. The perspective it provides supports improved customer-focused development and commercialization, and we and our customers can benefit from its use.”

​Jack Bailey ​President GlaxoSmithKline U.S.

“With pharmacy costs increasing so quickly, there is increasing pressure for P&T and Technology Assessment Committees to consider the value as well as the clinical efficacy of the drugs under evaluation. By providing an objective framework for assessing value, RxScorecard™ fills a gap in the existing toolkit available to health plans. And with greater discussion around narrower formularies, RxScorecard™ becomes even more important.”

​Michael S. Sherman, MD, MBA ​Senior Vice President and Chief Medical Officer Harvard Pilgrim Health Care

"RxScorecard™ lets a biopharma company anticipate the most important factors impacting the clinical & economic value of pipeline and marketed drugs -- and then helps identify the necessary changes to the clinical development and commercial program to maximize that value for all stakeholders, especially including payers. It's a required, straightforward, objective strategic tool that allows us to quickly and effectively adapt to a rapidly changing and much more challenging market access environment."

​Ammar Qadan ​Global Value/Market Access Lead Oncology Portfolio & Global Commercial Lead Oncology Biomarkers Halozyme Therapeutics, Inc.

"RxScorecard™ provides a comprehensive, multi-pronged rubric assisting us in decision-making as we begin to move from a volume to value drug evaluation methodology."

​Chronis H. Manolis, RPh ​Vice President, Pharmacy UPMC Health Plan

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888-670-8900
  • US Toll           : +1 908-547-2200
  • UK & Europe : +44 (20) 337 73737
  • Australia       : +61 2 8705 6907

Or email us your inquiry, so we can provide you the best possible customer service:
Pharma@informa.com

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: